Home-based care for advanced cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests the effects of home-based care on reducing unplanned hospitalizations within six months for advanced cancer patients with decreased performance status. The intervention includes education for patients and their family caregivers, home visits by specialized medical staff, and regular health check-ups. Participants will be recruited from six institutions, with a total of 396 cancer patients targeted for the study. The trial is designed as a cluster, non-randomized controlled trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Both the patient and their family caregiver must meet the criteria to be considered for this research.

1. Patient

   1. A person who has an advanced-stage solid cancer diagnosis (ICD-10 code C00-C70); A person who is receiving or planning to receive cancer treatment
   2. A person who meets one of the following conditions

      1. Has been evaluated as having ECOG performance status 2
      2. Has been evaluated as having ECOG performance status 1 and is over 70 years of age
   3. A person who wishes to stay at home
   4. A person whose family caregiver resides at home
   5. A person who wishes to participate in the research
2. Family Caregiver

   1. A family\* member of the patient

      \* Family: refers to the patient's spouse (including a common-law partner), descendants and their spouses up to the second degree, siblings and their spouses, and relatives and their spouses up to the eighth degree.
   2. A person who meets one of the following conditions:

      1. Lives with the patient (patient's household member)
      2. Does not live with the patient, but visits the patient's home more than three times a week
   3. A person who wants the patient to stay at home
   4. A person who can communicate easily with medical staff
   5. A person who wishes to participate in the research

Exclusion Criteria:

If either the patient or the family caregiver meets any one of these criteria, they are excluded from the study.

1. Patient

   1. A person who cannot speak, hear, or read Korean
   2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health
   3. A person residing outside the range that can be visited by the respective medical institution (the conditions for distance are to be specified by each medical institution)\*

      \* This condition is not applicable for the control group.
   4. A person who has used hospital- or home-type hospice and palliative care services
   5. A person who is under the age of 19
2. Family Caregiver

   1. A person who cannot speak, hear, or read Korean
   2. A person who is judged by a medical doctor to be unable to take part in this research due to extremely poor health
   3. A person under the age of 19

Where it's running

• Dongguk University Medical Center
  Goyang-si, Gyeonggi-do, South Korea Recruiting
• Bundang CHA Hospital
  Seongnam-si, Gyeonggi-do, South Korea Recruiting
• Seoul National University Bundang Hospital
  Seongnam-si, Gyeonggi-do, South Korea Recruiting
• Seoul National University Hospital
  Seoul, South Korea Recruiting
• Chung-Ang University Hosptial
  Seoul, South Korea Recruiting
• Kyung Hee University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Belong Cho, MD, MPH, PhD — Seoul National University Hospital
• Study coordinator: Ga-Young Lee
• Email: yoyo4284@snu.ac.kr
• Phone: 82-10-6527-3066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Nurse-led Integrated Home Health Service for Parents of Children Requiring Respiratory Support

  This study tests whether a nurse-led home health service helps parents better manage their child’s respiratory symptoms at home.

  Recruiting The Hong Kong Polytechnic University · Hong Kong and 1 other locations · NCT07652268

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.